The drug price hikes that are helping drive the health affordability crisis will continue for the rest of President Trump's ...

On Eli Lilly, UBS struck a more constructive tone, assuming coverage at Buy with a $1,250 price target. Analysts said Lilly ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Linda Burghardt, PhD, a researcher in Great Neck, New York, started taking semaglutide because her doctor thought it might ...

CMS has launched the BALANCE Model, a five-year test to lower costs & expand Medicare access to GLP-1 weight-loss drugs while ...

When I first started following news about GLP‑1 drugs, everything revolved around injections that patients had to store, ...

As Indiana enters 2026, a major shift in the healthcare landscape is promising to make high-demand weight-loss medications more accessible to millions. With ...

Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline ...